MARAVAI LIFESCIENCES HLDGS-A (MRVI) Stock Fundamental Analysis
USA - NASDAQ:MRVI - US56600D1072 - Common Stock
3.41 USD
-0.07 (-2.01%)
3.3801 USD
-0.03 (-0.88%)
MRVI gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 58 industry peers in the Life Sciences Tools & Services industry. MRVI scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. MRVI has a expensive valuation and it also scores bad on growth.
1. Profitability
1.1 Basic Checks
MRVI had negative earnings in the past year.
In the past year MRVI has reported a negative cash flow from operations.
The reported net income has been mixed in the past 5 years: MRVI reported negative net income in multiple years.
MRVI had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
MRVI's Return On Assets of -21.71% is on the low side compared to the rest of the industry. MRVI is outperformed by 68.42% of its industry peers.
Looking at the Return On Equity, with a value of -73.24%, MRVI is doing worse than 75.44% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -21.71% | ||
| ROE | -73.24% | ||
| ROIC | N/A |
ROA(3y)-4.24%
ROA(5y)0.56%
ROE(3y)-10.9%
ROE(5y)22.38%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
MRVI's Gross Margin of 29.11% is on the low side compared to the rest of the industry. MRVI is outperformed by 71.93% of its industry peers.
In the last couple of years the Gross Margin of MRVI has declined.
The Profit Margin and Operating Margin are not available for MRVI so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 29.11% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-20.26%
GM growth 5Y-4.76%
2. Health
2.1 Basic Checks
MRVI does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, MRVI has more shares outstanding
The number of shares outstanding for MRVI has been reduced compared to 5 years ago.
The debt/assets ratio for MRVI has been reduced compared to a year ago.
2.2 Solvency
MRVI has an Altman-Z score of 1.15. This is a bad value and indicates that MRVI is not financially healthy and even has some risk of bankruptcy.
MRVI has a Altman-Z score (1.15) which is comparable to the rest of the industry.
MRVI has a Debt/Equity ratio of 1.20. This is a high value indicating a heavy dependency on external financing.
The Debt to Equity ratio of MRVI (1.20) is worse than 77.19% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.2 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 1.15 |
ROIC/WACCN/A
WACC11.76%
2.3 Liquidity
A Current Ratio of 5.16 indicates that MRVI has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 5.16, MRVI is in the better half of the industry, outperforming 73.68% of the companies in the same industry.
A Quick Ratio of 4.49 indicates that MRVI has no problem at all paying its short term obligations.
The Quick ratio of MRVI (4.49) is better than 71.93% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 5.16 | ||
| Quick Ratio | 4.49 |
3. Growth
3.1 Past
The earnings per share for MRVI have decreased strongly by -1100.00% in the last year.
The Revenue for MRVI has decreased by -22.53% in the past year. This is quite bad
Measured over the past years, MRVI shows a quite strong growth in Revenue. The Revenue has been growing by 12.61% on average per year.
EPS 1Y (TTM)-1100%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-391.94%
Revenue 1Y (TTM)-22.53%
Revenue growth 3Y-31.3%
Revenue growth 5Y12.61%
Sales Q2Q%-35.43%
3.2 Future
MRVI is expected to show a very negative growth in Earnings Per Share. In the coming years, the EPS will decrease by -20.59% yearly.
The Revenue is expected to grow by 0.36% on average over the next years.
EPS Next Y-220.75%
EPS Next 2Y-45.21%
EPS Next 3Y-5.34%
EPS Next 5Y-20.59%
Revenue Next Year-26.2%
Revenue Next 2Y-11.02%
Revenue Next 3Y-4.63%
Revenue Next 5Y0.36%
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
MRVI reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for MRVI. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
MRVI's earnings are expected to decrease with -5.34% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-45.21%
EPS Next 3Y-5.34%
5. Dividend
5.1 Amount
No dividends for MRVI!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
3.41
-0.07 (-2.01%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)
Earnings (Next)
Inst Owners76.4%
Inst Owner Change-0.21%
Ins Owners5.33%
Ins Owner Change39.65%
Market Cap870.78M
Revenue(TTM)215.85M
Net Income(TTM)-194719000
Analysts76.47
Price Target4.08 (19.65%)
Short Float %12.05%
Short Ratio9.99
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-10.2%
Min EPS beat(2)-10.61%
Max EPS beat(2)-9.8%
EPS beat(4)0
Avg EPS beat(4)-55.61%
Min EPS beat(4)-154.98%
Max EPS beat(4)-9.8%
EPS beat(8)2
Avg EPS beat(8)-46.33%
EPS beat(12)4
Avg EPS beat(12)-39.93%
EPS beat(16)8
Avg EPS beat(16)-25.3%
Revenue beat(2)1
Avg Revenue beat(2)1.24%
Min Revenue beat(2)-1.9%
Max Revenue beat(2)4.37%
Revenue beat(4)1
Avg Revenue beat(4)-1.55%
Min Revenue beat(4)-5.38%
Max Revenue beat(4)4.37%
Revenue beat(8)4
Avg Revenue beat(8)-0.27%
Revenue beat(12)4
Avg Revenue beat(12)-1.33%
Revenue beat(16)7
Avg Revenue beat(16)-0.22%
PT rev (1m)-3.03%
PT rev (3m)-32.96%
EPS NQ rev (1m)-4.63%
EPS NQ rev (3m)-25.85%
EPS NY rev (1m)-2.29%
EPS NY rev (3m)-9.69%
Revenue NQ rev (1m)0.67%
Revenue NQ rev (3m)-1.93%
Revenue NY rev (1m)0.12%
Revenue NY rev (3m)-1.46%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 4.03 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 3.28 | ||
| P/tB | N/A | ||
| EV/EBITDA | N/A |
EPS(TTM)-0.24
EYN/A
EPS(NY)-0.21
Fwd EYN/A
FCF(TTM)-0.18
FCFYN/A
OCF(TTM)-0.08
OCFYN/A
SpS0.85
BVpS1.04
TBVpS-0.22
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -21.71% | ||
| ROE | -73.24% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 29.11% | ||
| FCFM | N/A |
ROA(3y)-4.24%
ROA(5y)0.56%
ROE(3y)-10.9%
ROE(5y)22.38%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-20.26%
GM growth 5Y-4.76%
F-Score4
Asset Turnover0.24
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.2 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 47.92% | ||
| Cap/Sales | 11.14% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 5.16 | ||
| Quick Ratio | 4.49 | ||
| Altman-Z | 1.15 |
F-Score4
WACC11.76%
ROIC/WACCN/A
Cap/Depr(3y)93.62%
Cap/Depr(5y)87.93%
Cap/Sales(3y)12.22%
Cap/Sales(5y)9.49%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-1100%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-391.94%
EPS Next Y-220.75%
EPS Next 2Y-45.21%
EPS Next 3Y-5.34%
EPS Next 5Y-20.59%
Revenue 1Y (TTM)-22.53%
Revenue growth 3Y-31.3%
Revenue growth 5Y12.61%
Sales Q2Q%-35.43%
Revenue Next Year-26.2%
Revenue Next 2Y-11.02%
Revenue Next 3Y-4.63%
Revenue Next 5Y0.36%
EBIT growth 1Y-148.83%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-1991.95%
EBIT Next 3Y183.62%
EBIT Next 5Y118.38%
FCF growth 1Y-116.86%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-106.74%
OCF growth 3Y-72.74%
OCF growth 5Y-20.9%
MARAVAI LIFESCIENCES HLDGS-A / MRVI FAQ
What is the ChartMill fundamental rating of MARAVAI LIFESCIENCES HLDGS-A (MRVI) stock?
ChartMill assigns a fundamental rating of 2 / 10 to MRVI.
What is the valuation status of MARAVAI LIFESCIENCES HLDGS-A (MRVI) stock?
ChartMill assigns a valuation rating of 0 / 10 to MARAVAI LIFESCIENCES HLDGS-A (MRVI). This can be considered as Overvalued.
Can you provide the profitability details for MARAVAI LIFESCIENCES HLDGS-A?
MARAVAI LIFESCIENCES HLDGS-A (MRVI) has a profitability rating of 1 / 10.
What is the earnings growth outlook for MARAVAI LIFESCIENCES HLDGS-A?
The Earnings per Share (EPS) of MARAVAI LIFESCIENCES HLDGS-A (MRVI) is expected to decline by -220.75% in the next year.